Community-acquired Pneumonia Due to Chlamydia Pneumoniae
ConditionCommunity-Acquired Pneumonia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier de Saint-Denis
About this trial
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
Availability of clinical data allowing confirmation of pneumonia diagnosis.
Disqualifiers
Patient opposition to the use of medical data for research purposes.
Absence of pneumonia diagnosis.
Insufficient clinical data for analysis.
Trial population
The study population consists of pediatric and adult patients from participating French and Swiss centers who had a positive simplex or multiplex PCR result for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025. Eligible patients must have a documented diagnosis of pneumonia and available clinical data allowing characterization of disease presentation, management, radiological findings, co-infections, and outcomes. Patients who objected to the use of their medical data for research purposes or who did not have pneumonia are excluded.
Trial design
Design model
Other
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR
Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.
Time frame
January 2015 to December 2025Secondary outcomes
1
Clinical Severity of Chlamydia pneumoniae Pneumonia
Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.
Time frame
From hospital admission through hospital discharge (up to 90 days)2
Radiological Characteristics
Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.
Time frame
Baseline (at the time of pneumonia diagnosis)3
Viral Co-Infection Rate
Proportion of patients with concomitant viral infection identified by microbiological testing.
Time frame
Baseline (at the time of PCR testing)4
Bacterial Co-Infection Rate
Proportion of patients with concomitant bacterial infection identified by microbiological testing.
Time frame
Baseline (at the time of PCR testing)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: